The Naples Prognostic Score Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment
Toru Aoyama,Aya Kato,Itaru Hashimoto,Yukio Maezawa,Kentaro Hara,Keisuke Kazama,Keisuke Komori,Hiroshi Tamagawa,Ayako Tamagawa,Shinsuke Nagasawa,Haruhiko Cho,Kenki Segami,Masato Nakazono,Kazuki Otani,Sho Sawazaki,Masakatsu Numata,Natsumi Kamiya,Suzue Yoshizawa,Shinnosuke Kawahara,Takashi Oshima,Aya Saito,Norio Yukawa,Yasushi Rino,TORU AOYAMA,AYA KATO,ITARU HASHIMOTO,YUKIO MAEZAWA,KENTARO HARA,KEISUKE KAZAMA,KEISUKE KOMORI,HIROSHI TAMAGAWA,AYAKO TAMAGAWA,SHINSUKE NAGASAWA,HARUHIKO CHO,KENKI SEGAMI,MASATO NAKAZONO,KAZUKI OTANI,SHO SAWAZAKI,MASAKATSU NUMATA,NATSUMI KAMIYA,SUZUE YOSHIZAWA,SHINNOSUKE KAWAHARA,TAKASHI OSHIMA,AYA SAITO,NORIO YUKAWA,YASUSHI RINO
DOI: https://doi.org/10.21873/invivo.13515
2024-01-01
In Vivo
Abstract:BACKGROUND/AIM: This study aimed to evaluate the clinical impact of the Naples Prognostic Score (NPS) in patients with gastric cancer and to clarify the potential of the NPS as a nutritional and inflammation evaluation system.PATIENTS AND METHODS: This study included 158 patients who underwent curative treatment for gastric cancer between 2005 and 2020. The prognosis and clinical pathological parameters of the high-NPS (NPS >2) and low-NPS (NPS=0, 1) groups were analyzed.RESULTS: The overall survival (OS) rates at 3 and 5 years were 86.7% and 77.7%, respectively, in the low-NPS group and 55.4% and 47.4%, respectively, in the high-NPS group. There were significant differences in OS between the two groups. Uni- and multivariate analyses demonstrated that the NPS was an independent prognostic factor for OS (HR=2.495, 95%CI=1.240-5.451). In addition, the 3- and 5-year recurrence-free survival (RFS) rates were 82.1% and 76.0%, respectively, in the NPS-low group, and 43.8% and 36.6% in the NPS-high group. Univariate and multivariate analyses demonstrated that the NPS was an independent prognostic factor for RFS (HR=2.739, 95%CI=1.509-4.972). When the first site of recurrence was compared between the low-NPS group and high-NPS group, there were significant differences in peritoneal recurrence (8.7% vs. 34.3%, p=0.001) and hematologic recurrence (5.6% vs. 21.9%, p=0.004).CONCLUSION: The NPS was a significant prognostic factor in patients with gastric cancer who received curative treatment. The NPS may be a promising biomarker for the treatment and management of gastric cancer.
medicine, research & experimental